Retrospective Evaluation of Minimally-Invasive Surgical Strategies in Ovarian Neoplasms (REMISSION Study)

Launched by JVAN CASARIN, MD PHD · Mar 10, 2025

Keywords

ClinConnect Summary

The REMISSION Study is a research trial looking at how well minimally invasive surgery, like laparoscopic or robotic surgery, works for women with early-stage epithelial ovarian cancer. The study will compare two groups of patients: one group will have minimally invasive surgery, while the other will have traditional open surgery. Researchers will examine how often patients experience complications after surgery, such as needing to return to the hospital or undergoing additional procedures. They will also assess cancer outcomes, including whether the cancer worsens during surgery and how long patients remain cancer-free after treatment.

To be eligible for this study, participants should be women diagnosed with early-stage epithelial ovarian cancer who had surgery between January 2014 and December 2023. They need to have had either minimally invasive or open surgery for their cancer. Patients can expect to contribute to important findings that could help future treatments and outcomes for others facing similar health challenges. Overall, this study aims to provide valuable insights into the best surgical options for treating early-stage ovarian cancer, particularly for women who want to preserve their fertility.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with apparent early-stage epithelial ovarian cancer at preoperative evaluation
• • 2. Patients who underwent surgery between January 2014 and December 2023
• • 3. Patients who underwent open or minimally invasive surgical staging (Laparoscopic or Robotic-assisted approach) or restaging procedure
• • 4. Patients with final pathology report of Epithelial Ovarian Cancer
• Exclusion Criteria:
• • 1. Patients who have not performed a complete surgical staging
• • 2. Patients who underwent neoadjuvant chemotherapy
• • 3. Patients with invasive synchronous tumor
• • 4. Patients with no informed consent
• • 5. Patients with ASA class score of 4 or 5